Targeting oncogenic Ras signaling in hematologic malignancies.

@article{Ward2012TargetingOR,
  title={Targeting oncogenic Ras signaling in hematologic malignancies.},
  author={Ashley F. Ward and Benjamin S. Braun and Kevin M. Shannon},
  journal={Blood},
  year={2012},
  volume={120 17},
  pages={3397-406}
}
Ras proteins are critical nodes in cellular signaling that integrate inputs from activated cell surface receptors and other stimuli to modulate cell fate through a complex network of effector pathways. Oncogenic RAS mutations are found in ∼25% of human cancers and are highly prevalent in hematopoietic malignancies. Because of their structural and biochemical properties, oncogenic Ras proteins are exceedingly difficult targets for rational drug discovery, and no mechanism-based therapies exist… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 61 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 113 references

Selec - tive FLT 3 inhibition of FLT 3ITD (  ) acute myeloid leukaemia resulting in secondary D 835 Y mutation : a model for emerging clinical resistance patterns

  • AS Moore, A Faisal, DG deCastro
  • Leukemia
  • 2012

The GATA 2 transcriptional network is requisite for RAS oncogenedriven non - small

  • MS Kumar, DC Hancock, M Molina-Arcas
  • cell lung cancer Cell
  • 2012

Similar Papers

Loading similar papers…